Patent assignee · US · COMPANY

Signpath Pharma Inc.

🏢 View company profile →
23Patents
23Active
23Granted
51Portfolio score

Filing activity: Dec 1, 2007 → Nov 5, 2021 · 1 expiring within 5 years

Most-cited patents

PatentTitleAreaCited byStatus
US8753674B2 Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current Emerging Cross-Sectional Technologies 27 Active
US9682041B2 Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current Emerging Cross-Sectional Technologies 19 Active
US10357458B2 Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current Emerging Cross-Sectional Technologies 15 Active
US10117881B2 Protective effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs that cause channelopathies Physics 15 Active
US10238602B2 Protective effect of DMPC, DMPG, DMPC/DMPG, LysoPG and LysoPC against drugs that cause channelopathies Physics 15 Active
US10258691B2 Protective effect of DMPC, DMPG, DMPC/DMPG, EGPG, LysoPG and LysoPC against drugs that cause channelopathies Physics 15 Active
US8747890B2 Intravenous infusion of curcumin and a calcium channel blocker Human Necessities 14 Active
US10449193B2 Protective effect of DMPC, DMPG, DMPC/DMPG, lysoPG and lysoPC against drugs that cause channelopathies Physics 13 Active
US9138411B2 Curcumin-ER, a liposomal-PLGA sustained release nanocurcumin for minimizing QT prolongation for cancer therapy Human Necessities 12 Active
US10532045B2 Liposomal mitigation of drug-induced inhibition of the cardiac IKr channel Human Necessities 6 Active
US10617639B2 Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current Emerging Cross-Sectional Technologies 5 Active
US8784881B2 Liposomal curcumin for treatment of diseases Human Necessities 3 Active
US10975111B2 Cardiopathy-reducing phosphodiester lipids Human Necessities 2 Active
US10485768B2 Treatment for glioblastoma Human Necessities 2 Active
US10004687B2 Liposomal curcumin for treatment of diseases Human Necessities 1 Active
US9170257B2 Method and system for measuring the pharmacokinetics of liposomal curcumin and its metabolite tetrahydrocurcumin Physics 0 Active
US11643424B2 Cardiopathy-reducing phosphodiester lipids Human Necessities 0 Active
US11813356B2 Dosing regimens for treatment of proliferative disorders Human Necessities 0 Active
US11746119B2 Cardiopathy-reducing phosphodiester lipids Human Necessities 0 Active
US10739353B2 Suppression of cytokine release and cytokine storm Emerging Cross-Sectional Technologies 0 Active
US11806401B2 Prevention of drug-induced atrio-ventricular block Human Necessities 0 Active
US9393198B2 Intravenous curcumin and derivatives for treatment of neurodegenerative and stress disorders Human Necessities 0 Active
US12004868B2 Liposomal mitigation of drug-induced inhibition of the cardiac IKr channel Human Necessities 0 Active

Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.